Results of an internal dose assessment intercomparison exercise after a EURADOS/IAEA training course

2010 ◽  
Vol 144 (1-4) ◽  
pp. 592-595 ◽  
Author(s):  
C.- M. Castellani ◽  
M. A. Lopez ◽  
A. Luciani ◽  
J. W. Marsh ◽  
T. Vrba ◽  
...  
2007 ◽  
Vol 127 (1-4) ◽  
pp. 317-320 ◽  
Author(s):  
C. Hurtgen ◽  
A. Andrasi ◽  
M. R. Bailey ◽  
A. Birchall ◽  
E. Blanchardon ◽  
...  

2006 ◽  
Vol 125 (1-4) ◽  
pp. 56-60 ◽  
Author(s):  
H. Doerfel ◽  
A. Andrasi ◽  
R. Cruz-Suarez ◽  
C.-M. Castellani ◽  
C. Hurtgen ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
C. Rääf ◽  
V. Barkauskas ◽  
K. Eriksson Stenström ◽  
C. Bernhardsson ◽  
H. B. L. Pettersson

AbstractThe pure alpha emitter 148Gd may have a significant radiological impact in terms of internal dose to exposed humans in case of accidental releases from a spallation source using a tungsten target, such as the one to be used in the European Spallation Source (ESS). In this work we aim to present an approach to indirectly estimate the whole-body burden of 148Gd and the associated committed effective dose in exposed humans, by means of high-resolution gamma spectrometry of the gamma-emitting radiogadolinium isotopes 146Gd and 153Gd that are accompanied by 148Gd generated from the operation of the tungsten target. Theoretical minimum detectable whole-body activity (MDA) and associated internal doses from 148Gd are calculated using a combination of existing biokinetic models and recent computer simulation studies on the generated isotope ratios of 146Gd/148Gd and 153Gd/148Gd in the ESS target. Of the two gamma-emitting gadolinium isotopes, 146Gd is initially the most sensitive indicator of the presence of 148Gd if whole-body counting is performed within a month after the release, using the twin photo peaks of 146Gd centered at 115.4 keV (MDA < 1 Bq for ingested 148Gd, and < 25 Bq for inhaled 148Gd). The corresponding minimum detectable committed effective doses will be less than 1 µSv for ingested 148Gd, but substantially higher for inhaled 148Gd (up to 0.3 mSv), depending on operation time of the target prior to the release. However, a few months after an atmospheric release, 153Gd becomes a much more sensitive indicator of body burdens of 148Gd, with a minimum detectable committed effective doses ranging from 18 to 77 µSv for chronic ingestion and between 0.65 to 2.7 mSv for acute inhalation in connection to the release. The main issue with this indirect method for 148Gd internal dose estimation, is whether the primary photon peaks from 146 and 153Gd can be detected undisturbed. Preliminary simulations show that nuclides such as 182Ta may potentially create perturbations that could impair this evaluation method, and which impact needs to be further studied in future safety assessments of accidental target releases.


2008 ◽  
Vol 95 (suppl 2) ◽  
pp. S137-S142 ◽  
Author(s):  
D LePoire ◽  
P Richmond ◽  
J -J. Cheng ◽  
S Kamboj ◽  
J Arnish ◽  
...  

2016 ◽  
Vol 173 (1-3) ◽  
pp. 192-197
Author(s):  
Nancy Puerta Yepes ◽  
Ana Rojo ◽  
Sebastián Gossio ◽  
José Luis Crudo

2007 ◽  
Vol 127 (1-4) ◽  
pp. 240-244 ◽  
Author(s):  
S. Lamart ◽  
L. de Carlan ◽  
E. Blanchardon ◽  
D. Franck

Sign in / Sign up

Export Citation Format

Share Document